HALO

Halozyme Therapeutics Inc. (HALO) | Rumor.io

Halozyme Therapeutics

HALO

Attention (50-day avg)0%

Attention rank (50-day avg)#921

Bullish sentiment (50-day avg)100%

Price to earnings ratio33.1

Market capitalization12.8B

Earnings per share3.41

Dividend yield (TTM)—

Revenue (annual)1.4B

Net income (annual)316.9M

Social

What share of all stock conversation is about HALO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 7

$HALO has been upgraded by several analysts, including HC Wainwright, Leerink, and Morgan Stanley, with target prices ranging from $95 to $115.
The company has seen significant revenue growth, with a 48% increase YoY in Q2, and royalties also up 50%.
Analysts are optimistic about the company's future, with Morgan Stanley highlighting "deal engine accelerating and curve bending into 2029+" and H.C. Wainwright noting "outstanding company" with a "crazy low valuation".

Generated by AI

Sentiment

Of the messages about HALO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	96.88% -2.97	94.7% +2.42
Bearish	—	0% 0	3.13% +2.97	5.3% -2.42

Bullish· Aug 6

Halozyme Therapeutics, Inc. (HALO) has been upgraded by multiple analysts, including JMP Securities, Morgan Stanley, and HC Wainwright, with price targets ranging from $75 to $91.
The company has beaten Q2 estimates and raised guidance, with revenue growth of 41% YoY and adjusted EPS of $1.54, exceeding consensus expectations.
The regulatory outlook for Halozyme has improved, with Morgan Stanley citing the passing of the One Big Beautiful Bill as a positive read-through, which may alleviate regulatory uncertainties and unlock continued royalty revenue growth.

Bearish· Jan 17

The failure of Halozyme's pancreatic cancer trial has raised concerns about the effectiveness of its PEGPH20 treatment, potentially reducing confidence in its pivotal trial.
The early termination of the trial has sparked concerns about the company's ability to deliver on its product pipeline, leading to a decline in investor confidence.
The stock's volatility and the potential for further price drops have led some investors to exit their positions, with some even expressing regret for selling at lower prices.

Generated by AI

Topics

Of the messages about HALO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	93.75%	22.3%
Analysts	—	—	3.13%	36.82%
Earnings	—	—	0%	3.56%
Technical Analysis	—	—	3.13%	7.19%
Macro	—	—	0%	28.04%
Controversies	—	—	0%	2.08%

Earnings· Aug 7

Halozyme Therapeutics beats earnings estimates by $0.06, reports FQ2 earnings of -$0.16 EPS and $35.20M in revenue.
The company beats Estimize EPS consensus by 4 cents and revenue consensus by $2.84M.
Halozyme Therapeutics reports a loss of $0.16, which is better than the consensus estimate of a loss of $0.22.

Announcements· Jan 11

Halozyme Therapeutics, Inc. (HALO) announces redemption of 1.25% convertible senior notes due 2024.
The redemption is expected to reduce debt and improve the company's financial position.
HALO's stock price declined sharply after the company provided downside FY23 guidance.

Technical Analysis· Jan 5

$HALO is testing support at $12.00, with potential for a squeeze if it breaks above $12.80.
A bull cross-over on the MACD and rising full stochastics suggest $HALO is going up, with potential for a breakout if it breaks above $12.50.
$HALO has significant resistance around $12.23 and $12.80, with a 50k print at $13.40 that could act as a magnet if support holds at $12.

Generated by AI

Community

Of the messages about HALO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	91.67%	93.93%	42.21%
Newcomers	—	8.33%	6.07%	57.79%

Regulars· Jun 6

Halozyme Therapeutics has raised its full-year revenue and earnings guidance due to a new European patent, with shares reaching a new 52-week high.
The company has announced the issuance of a new European patent for its ENHANZE drug delivery platform, which is expected to drive future growth.
Halozyme's full-year 2024 financial guidance has been raised, and the company has updated its 5-year financial outlook, with shares trading at significantly above-average volume.

Newcomers· Feb 17

Newcomers are focusing on the company's record revenue beat in Q4 2025, driven by its royalty engine, with a 52% YoY growth.
The Q4 earnings report highlighted a one-time IPR&D charge from an acquisition, which led to a net income collapse and an earnings per share "miss".
The company's guidance for 2026 revenue, adjusted EBITDA, and EPS has been reiterated, with a projected increase in EPS due to the accretive impact of recent acquisitions.

Generated by AI

Halozyme Therapeutics (NASDAQ:HALO) has outperformed the market over the past 15 years by 8.16% on an annualized basis producing an average annual return of 21.6%. Currently, Halozyme Therapeutics has a market

6d agoBenzinga

If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now

6d agoYahoo Finance

Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?

Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

7d agoYahoo Finance

Halozyme Therapeutics completes $1.5 billion convertible notes offering

7d agoInvesting.com

Halozyme (HALO) Just Made A $1.3B Bet On Itself

On September 17, Halozyme (NASDAQ:HALO) priced $1.3 billion of convertible senior notes due 2033, an offering that grew from an originally planned $1.05 billion as demand came in. The notes carry a 1.50% coupon and convert into stock at $139.84 a share, a 27.5% premium to the $109.68 closing price that day. Investors who like […]

8d agoYahoo Finance

Halozyme Therapeutics (HALO) Proposes $1.05B in Convertibles. Is More Time Worth the Cost?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on September 16 a proposed $1.05 billion offering of convertible senior notes due October 1, 2033. The plan includes an expected option for initial purchasers to buy another $150 million. The interest rate and initial conversion terms were to be determined at pricing. Halozyme Therapeutics, Inc. (NASDAQ:HALO) intends to use […]

9d agoYahoo Finance

Also Discussed

Investors talking about HALO also mention

#	Name	Attention
1	FOLD - Amicus Therapeutics, Inc.	——
2	iShares Biotechnology ETFIBB	0.01%0
3	Acadia Pharmaceuticals Inc.ACAD	0%+0
4	MACK - Merrimack Pharmaceuticals, Inc.	——
5	EGRX - Eagle Pharmaceuticals, Inc.	——
6	Cytokinetics, IncorporatedCYTK	0.01%+0
7	Celldex Therapeutics IncCLDX	0%0
8	Nektar TherapeuticsNKTR	0.08%+0.03
9	Exelixis Inc.EXEL	0%-0.03
10	HZNP - Horizon Therapeutics Public Limited Company	——

Halozyme Therapeutics Inc.

Healthcare
Biotechnology

Halozyme Therapeutics Inc. is a biopharmaceutical technology company focused on drug delivery solutions and specialty medicines. Its core platform, ENHANZE, uses the proprietary enzyme rHuPH20 to help enable subcutaneous delivery of injectable therapies and fluids, supporting more convenient administration and improved patient comfort. The company also develops, manufactures, and commercializes drug-device combination products with advanced auto-injector technology for use in areas such as oncology and other specialty therapeutic settings. In addition to its platform business, Halozyme Therapeutics Inc. markets proprietary products including Hylenex and XYOSTED, and works with pharmaceutical partners to support a range of commercial and development-stage programs. Headquartered in San Diego, California, Halozyme Therapeutics Inc. plays a specialized role in the biopharmaceutical market by providing technologies that help improve how existing medicines are delivered and used.

Website

Location

12390 El Camino Real

San Diego, CA, 92130

United States

Social

What share of all stock conversation is about HALO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 7

$HALO has been upgraded by several analysts, including HC Wainwright, Leerink, and Morgan Stanley, with target prices ranging from $95 to $115.
The company has seen significant revenue growth, with a 48% increase YoY in Q2, and royalties also up 50%.
Analysts are optimistic about the company's future, with Morgan Stanley highlighting "deal engine accelerating and curve bending into 2029+" and H.C. Wainwright noting "outstanding company" with a "crazy low valuation".

Generated by AI

Sentiment

Of the messages about HALO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	96.88% -2.97	94.7% +2.42
Bearish	—	0% 0	3.13% +2.97	5.3% -2.42

Bullish· Aug 6

Halozyme Therapeutics, Inc. (HALO) has been upgraded by multiple analysts, including JMP Securities, Morgan Stanley, and HC Wainwright, with price targets ranging from $75 to $91.
The company has beaten Q2 estimates and raised guidance, with revenue growth of 41% YoY and adjusted EPS of $1.54, exceeding consensus expectations.
The regulatory outlook for Halozyme has improved, with Morgan Stanley citing the passing of the One Big Beautiful Bill as a positive read-through, which may alleviate regulatory uncertainties and unlock continued royalty revenue growth.

Bearish· Jan 17

The failure of Halozyme's pancreatic cancer trial has raised concerns about the effectiveness of its PEGPH20 treatment, potentially reducing confidence in its pivotal trial.
The early termination of the trial has sparked concerns about the company's ability to deliver on its product pipeline, leading to a decline in investor confidence.
The stock's volatility and the potential for further price drops have led some investors to exit their positions, with some even expressing regret for selling at lower prices.

Generated by AI

Topics

Of the messages about HALO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	93.75%	22.3%
Analysts	—	—	3.13%	36.82%
Earnings	—	—	0%	3.56%
Technical Analysis	—	—	3.13%	7.19%
Macro	—	—	0%	28.04%
Controversies	—	—	0%	2.08%

Earnings· Aug 7

Halozyme Therapeutics beats earnings estimates by $0.06, reports FQ2 earnings of -$0.16 EPS and $35.20M in revenue.
The company beats Estimize EPS consensus by 4 cents and revenue consensus by $2.84M.
Halozyme Therapeutics reports a loss of $0.16, which is better than the consensus estimate of a loss of $0.22.

Announcements· Jan 11

Halozyme Therapeutics, Inc. (HALO) announces redemption of 1.25% convertible senior notes due 2024.
The redemption is expected to reduce debt and improve the company's financial position.
HALO's stock price declined sharply after the company provided downside FY23 guidance.

Technical Analysis· Jan 5

$HALO is testing support at $12.00, with potential for a squeeze if it breaks above $12.80.
A bull cross-over on the MACD and rising full stochastics suggest $HALO is going up, with potential for a breakout if it breaks above $12.50.
$HALO has significant resistance around $12.23 and $12.80, with a 50k print at $13.40 that could act as a magnet if support holds at $12.

Generated by AI

Community

Of the messages about HALO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	91.67%	93.93%	42.21%
Newcomers	—	8.33%	6.07%	57.79%

Regulars· Jun 6

Halozyme Therapeutics has raised its full-year revenue and earnings guidance due to a new European patent, with shares reaching a new 52-week high.
The company has announced the issuance of a new European patent for its ENHANZE drug delivery platform, which is expected to drive future growth.
Halozyme's full-year 2024 financial guidance has been raised, and the company has updated its 5-year financial outlook, with shares trading at significantly above-average volume.

Newcomers· Feb 17

Newcomers are focusing on the company's record revenue beat in Q4 2025, driven by its royalty engine, with a 52% YoY growth.
The Q4 earnings report highlighted a one-time IPR&D charge from an acquisition, which led to a net income collapse and an earnings per share "miss".
The company's guidance for 2026 revenue, adjusted EBITDA, and EPS has been reiterated, with a projected increase in EPS due to the accretive impact of recent acquisitions.

Generated by AI

Halozyme Therapeutics

Social

Aug 7

Bullish· Aug 6

Bearish· Jan 17

Earnings· Aug 7

Announcements· Jan 11

Technical Analysis· Jan 5

Regulars· Jun 6

Newcomers· Feb 17

$1000 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth This Much Today - Halozyme Therapeuti

If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now

Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?

Halozyme Therapeutics completes $1.5 billion convertible notes offering

Halozyme (HALO) Just Made A $1.3B Bet On Itself

Halozyme Therapeutics (HALO) Proposes $1.05B in Convertibles. Is More Time Worth the Cost?

Also Discussed

Halozyme Therapeutics Inc.

Company Information

Location

$1000 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth This Much Today - Halozyme Therapeuti

If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now

Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?

Halozyme Therapeutics completes $1.5 billion convertible notes offering

Halozyme (HALO) Just Made A $1.3B Bet On Itself

Halozyme Therapeutics (HALO) Proposes $1.05B in Convertibles. Is More Time Worth the Cost?

Also Discussed

Social

Aug 7

Bullish· Aug 6

Bearish· Jan 17

Earnings· Aug 7

Announcements· Jan 11

Technical Analysis· Jan 5

Regulars· Jun 6

Newcomers· Feb 17